▎MindRank Content Team Report

On September 8, MindRank announced that its self-developedOral Small Molecule GLP-1 Receptor Agonist (GLP-1RA)MDR-001 Successfully Completed TargetingObese SubjectsThe first dosing group in the Phase 2a clinical trial has been administered. This study employs a randomized, double-blind, placebo-controlled design to explore the long-term dosing regimen of MDR-001 in obese subjects, as well as its pharmacokinetic profile, safety, tolerability, and efficacy.

Glucagon-Like Peptide-1 (GLP-1)It is a peptide hormone secreted by intestinal cells. By binding to the GLP-1 receptor, it stimulates insulin secretion and inhibits glucagon secretion, thereby promoting glucose metabolism.At the same time, it can also delay gastric emptying and suppress appetite. Therefore,GLP-1 is consideredIs a powerful target for the treatment of obesity and type 2 diabetes.

MDR-001 is a β-arrestin 2 highly selective GLP-1R agonist developed by MindRank. It is reported that,This drug not only retains the islet cell repair and protection functions brought by β-arrestin recruitment but also avoids the restricted insulin secretion and mediated endocytosis desensitization caused by β-arrestin 1 recruitment., with obvious differential characteristics and potential clinical advantages.

Preclinical studies have found that MDR-001 demonstrated excellent in vivo and in vitro efficacy and drug-like properties, including significantly improved PK and safety window. Meanwhile, in early-stage diabetic and obese monkey models, long-term administration of MDR-001 not only effectively reduced blood glucose and body weight but also restored HbA1c to the level of healthy monkeys. No rebound was observed during the recovery period after discontinuation, suggesting that the drug may help repair damaged islet cells and restore islet function, showing the potential to "cure" early-stage diabetes.

According toMindRank Press Release Introduction,MDR-001 has currently completed the preliminary Phase 1 single-dose escalation study. Preliminary clinical research results show that MDR-001 has good safety and pharmacokinetic characteristics, with a clear linear relationship observed across different dose groups, and its preclinical feature advantages have been well translated into clinical practice.